tradingkey.logo
搜索

Bioventus Inc

BVS
添加自选
13.170USD
-0.010-0.08%
收盘 07-31 16:00美东报价延迟15分钟
892.24M总市值
30.81市盈率 TTM

关于 Bioventus Inc 公司

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Bioventus Inc简介

公司代码BVS
公司名称Bioventus Inc
上市日期Feb 11, 2021
CEOClaypoole (Robert E)
员工数量930
证券类型Ordinary Share
年结日Feb 11
公司地址4721 Emperor Boulevard, Suite 100
城市DURHAM
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编27703
电话19194746700
网址https://www.bioventus.com/
公司代码BVS
上市日期Feb 11, 2021
CEOClaypoole (Robert E)

Bioventus Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Katrina Church, J.D.
Ms. Katrina Church, J.D.
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
--
--
Mr. William A. (Bill) Hawkins, III
Mr. William A. (Bill) Hawkins, III
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Guy Paul Nohra
Mr. Guy Paul Nohra
Independent Director
Independent Director
--
--
Marty Sutter ,
Marty Sutter ,
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--

常见问题

Bioventus Inc的前五大股东是谁?

Bioventus Inc 的前五大股东如下:Ms. Susan M. Stalnecker

有多少机构持有Bioventus Inc(BVS)的股份?

截至2026Q1,共有339家机构持有Bioventus Inc的股份,合计持有的股份价值约为52.51M,占公司总股份的77.51%。与2025Q4相比,机构持股有所增加,增幅为-10203484.00。

哪个业务部门对Bioventus Inc的收入贡献最大?

在2026Q1,Pain Treatments业务部门对Bioventus Inc的收入贡献最大,创收279.06M,占总收入的49.12%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有